VERTEX PHARMACEUTICALS
Vertex Pharmaceuticals is a biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.
VERTEX PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
1989-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.vrtx.com
Total Employee:
1001+
Status:
Active
Contact:
617-341-6100
Total Funding:
657.31 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Tag Manager Google Analytics Content Delivery Network LetsEncrypt Font Awesome Mobile Non Scaleable Content
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Exelixis
Exelixis works is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases.
GT Biopharma
GT Biopharma specializes in the research and development of therapeutic products used primarily for the treatment of cancer.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a drugmaker company.
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Synta Pharmaceuticals
Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Bausch Health
Bausch Health is a develops and markets medications used in the fields of neurology, dermatology and infectious diseases.
Current Advisors List
Board_member
Board_member
Board_member
Advisor
2010-01-01
Board_member
Board_member
2019-02-01
Board_member
2012-09-01
Board_member
1997-01-01
Current Employees Featured
Reshma Kewalramani President and Chief Executive Officer @ Vertex Pharmaceuticals
President and Chief Executive Officer
2020-04-01
Jeffrey Leiden Executive Chairman @ Vertex Pharmaceuticals
Executive Chairman
2020-04-01
Nina Devlin Senior Vice President and Chief Communications Officer @ Vertex Pharmaceuticals
Senior Vice President and Chief Communications Officer
2019-01-01
Ludovic Fenaux Senior Vice President, International Commercial Operations @ Vertex Pharmaceuticals
Senior Vice President, International Commercial Operations
Megan Krench Director of BD - External Innovation @ Vertex Pharmaceuticals
Director of BD - External Innovation
2020-02-01
Brian Goldman Research Fellow @ Vertex Pharmaceuticals
Research Fellow
Mark Hollison Procurement and Strategic Sourcing Director @ Vertex Pharmaceuticals
Procurement and Strategic Sourcing Director
John Gray Senior Vice President, Genetic Therapies Research @ Vertex Pharmaceuticals
Senior Vice President, Genetic Therapies Research
David Altshuler Executive Vice President, Global Research and Chief Scientific Officer @ Vertex Pharmaceuticals
Executive Vice President, Global Research and Chief Scientific Officer
2015-01-01
Glenn Butcher Sr Director, Global Digital Marketing @ Vertex Pharmaceuticals
Sr Director, Global Digital Marketing
2016-02-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-04-10 | Alpine Immune Sciences | Alpine Immune Sciences acquired by Vertex Pharmaceuticals | 4.9 B USD |
| 2023-09-12 | Septerna | Septerna acquired by Vertex Pharmaceuticals | N/A |
| 2022-07-11 | ViaCyte | ViaCyte acquired by Vertex Pharmaceuticals | 320 M USD |
| 2022-03-07 | Vectrus | Vectrus acquired by Vertex Pharmaceuticals | 2.1 B USD |
| 2019-09-03 | Semma Therapeutics | Semma Therapeutics acquired by Vertex Pharmaceuticals | 950 M USD |
| 2019-06-06 | Exonics Therapeutics | Exonics Therapeutics acquired by Vertex Pharmaceuticals | 245 M USD |
| 2009-03-12 | ViroChem Pharma | ViroChem Pharma acquired by Vertex Pharmaceuticals | 400 M USD |
| 2001-04-30 | Aurora Biosciences Corporation | Aurora Biosciences Corporation acquired by Vertex Pharmaceuticals | N/A |
Investors List
J.P. Morgan Securities Inc.
J.P. Morgan Securities Inc. investment in Post-IPO Equity - Vertex Pharmaceuticals
Bank of America Merrill Lynch
Bank of America Merrill Lynch investment in Post-IPO Equity - Vertex Pharmaceuticals
Morgan Stanley
Morgan Stanley investment in Post-IPO Equity - Vertex Pharmaceuticals
Goldman Sachs
Goldman Sachs investment in Post-IPO Equity - Vertex Pharmaceuticals
Janssen Belgium
Janssen Belgium investment in Post-IPO Equity - Vertex Pharmaceuticals
Norwest Venture Partners
Norwest Venture Partners investment in Venture Round - Vertex Pharmaceuticals
J.H. Whitney & Co
J.H. Whitney & Co investment in Venture Round - Vertex Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Venture Round - Vertex Pharmaceuticals
Greylock
Greylock investment in Venture Round - Vertex Pharmaceuticals
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-11-09 | Arbor Biotechnologies | Vertex Pharmaceuticals investment in Series B - Arbor Biotechnologies | 215 M USD |
| 2020-03-12 | Kymera Therapeutics | Vertex Pharmaceuticals investment in Series C - Kymera Therapeutics | 102 M USD |
| 2018-12-09 | Genomics | Vertex Pharmaceuticals investment in Series B - Genomics | 8 M EUR |
| 2018-08-30 | Genomics | Vertex Pharmaceuticals investment in Series B - Genomics | 25 M GBP |
| 2017-12-06 | Obsidian Therapeutics | Vertex Pharmaceuticals investment in Series A - Obsidian Therapeutics | 49.5 M USD |
| 2015-04-30 | CRISPR Therapeutics | Vertex Pharmaceuticals investment in Series B - CRISPR Therapeutics | 29 M USD |
Newest Events participated
Participated in Forbes Under 30 Summit 2016
on 2016-10-16 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-09-08 | Vertex Appoints Jonathan Biller as Chief Legal Officer |
| 2021-08-04 | Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer |
Official Site Inspections
http://www.vrtx.com Semrush global rank: 252.29 K Semrush visits lastest month: 163.15 K
- Host name: 45.60.0.246
- IP address: 45.60.0.246
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vertex Pharmaceuticals"
Vertex Pharmaceuticals | Our Company
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.See details»
Vertex Pharmaceuticals - Wikipedia
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, EnglandSee details»
Investor Relations | Vertex Pharmaceuticals
Investorinfo@VRTX.com +1(617)-961-7163. Contacting Vertex's Transfer Agent. Communication regarding transfer requirements, lost certificates and changes of address should be directed …See details»
Newsroom | Vertex Pharmaceuticals Newsroom
Mediainfo@vrtx.com +1 617 341 6992 +44 20 3204 5275. Newsroom Site - Hero Circle Menu. Leadership Team. R&D Pipeline. Media Library. Videos. Latest Press Releases Jan 27 2025. …See details»
Contact Us | Vertex Pharmaceuticals - vrtx.ca
Office Address: 20 Bay Street, Suite 1520 Toronto, Ontario M5J 2N8 Canada. Main Numbers/General Information: +1 647 790 1600 Medical Information: For medical information …See details»
Reports and Resources | Vertex Pharmaceuticals Newsroom
Mediainfo@vrtx.com +1 617 341 6992 +44 20 3204 5275. Reports and Resources Categories. Corporate Fact Sheet. Corporate Fact Sheet 1.4 MB. Sweat Chloride Media Toolkit. Sweat …See details»
Our Commitment to Research | Vertex Pharmaceuticals …
At Vertex, we are a science-led organization. Three out of five Vertex employees are dedicated to research and development (R&D) and we invest more of our operating expenses in R&D than pharmaceutical industry averages. We …See details»
Vertex Pharmaceuticals | Our Science
A portfolio approach to development. When we decide to work on a disease, we investigate it from every angle. For example, our sickle cell disease and beta thalassemia programs include multiple approaches.See details»
News & Events - investors.vrtx.com
1 day ago BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has …See details»
Vertex Reports Third Quarter 2024 Financial Results | Vertex ...
Sep 30, 2024 Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Vertex’s business, particularly those risks listed under …See details»
Vertex Pharmaceuticals | Responsibility | Vertex Volunteers and ...
We support Vertex employees who serve on the boards of nonprofits by offering access to tools and resources to develop leadership skills and financial support for the organization with which …See details»
Vertex Pharmaceuticals | Careers
Interested Applicants: Please be aware of the potential for scams from individuals, organizations and internet sites that claim to represent Vertex Pharmaceuticals Incorporated in recruitment …See details»
Vertex and the Vertex Foundation Commit $4 Million to Support …
Jun 25, 2020 BOSTON--(BUSINESS WIRE)--Jun. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex and the Vertex Foundation, ... City …See details»
Press Release - news.vrtx.com
4 days ago BOSTON--(BUSINESS WIRE)--Jan. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, …See details»
Press Releases - Vertex Pharmaceuticals
Dec 23, 2024 BOSTON --(BUSINESS WIRE)--Jan. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results …See details»
What's Happening With VRTX Stock? - Forbes
1 hour ago The increase in VRTX stock over the recent years has been far from consistent, and has largely been as volatile as the S&P 500. Returns for the stock were -7% in 2021, 32% in …See details»
Vertex Pharmaceuticals’ JOURNA VX: Navigating ... - Markets Insider
15 hours ago Vertex Pharmaceuticals (VRTX) Company Description: Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, …See details»
Vertex Pain Drug Gets FDA Nod as Safer Alternative to Opioids
16 hours ago Vertex Pharmaceuticals Inc. gained US approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have …See details»
The FDA Just Approved a New Pain Med Journavx (Suzetrigine)
15 hours ago The Newly Approved Pain Med Journavx Brings Hope to Millions. This non-opioid option for treating acute pain is the first new approach on the market in decades.See details»
Vertex Pharmaceuticals (VRTX) Receives a Hold from Scotiabank
15 hours ago In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $433.00. …See details»